NCT05326152

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

Intralesional or Intramuscular Hepatitis B Vaccine Versus Intralesional Saline in the Treatment of Multiple Common Warts

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 10 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Assessment of the effectiveness of intralesional and intramuscular hepatitis B vaccine in treatment of multiple common warts.

Detailed description

Recently, intralesional immunotherapy by different antigens, including Candida antigen and purified protein derivative PPD has been proved effective in the treatment of different types of warts. Hepatitis B vaccine is one of the DNA vaccines that are regarded as being potentially safer, relatively cheap and easy to produce with no special storage requirements because they are extremely stable and allow for potential simultaneous immunization against multiple antigens or pathogens via co-expression of multiple epitopes on single plasmid. Hepatitis B vaccine could be a promising immunotherapeutic vaccine in the field of intralesional immunotherapy of warts. Moreover, the efficacy of intramuscular injection of hepatitis B vaccine would be assessed and compared to its intralesional injection.

Conditions

• Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts

Interventions

Type	Name	Description
BIOLOGICAL	hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)	Randomized placebo-controlled comparative effectiveness clinical trial
BIOLOGICAL	Intralesional saline	Intralesional saline

Timeline

• Start date: 2020-11-25
• Primary completion: 2021-06-20
• Completion: 2021-10-25
• First posted: 2022-04-13
• Last updated: 2022-04-13

Locations

1 site across 1 country: Egypt